Active Biotechnology & Medical Venture Capital Investors

Interests in biotechnology & medical industries continue to attract interests from investors, turmoils in Euro zone however, may have caused some uncertainties in terms of European venture capital investors investing into  North American opportunities due to volatility in exchange rates.

Nevertheless, investments have not stopped flowing into this sector, here are some more investors for you to consider in the world of biotechnology/medical investments:

Baird Venture Partners (US)

Baird Venture Partners is an emerging biotechnology / life-science venture capital firm. The company currently has US$200m plus venture capital fund focus on biotechnology and life science sectors.
Baird Venture Partners, the U.S.-based venture capital fund of Baird Private Equity, makes investments in early- and expansion-stage companies in the Business Services and Healthcare/Life Sciences sectors.

In the Healthcare / Life Sciences sectors, they are especially focused on Medical Devices / Equipment sectors, including information management (healthcare IT (HIT)) opportunities; as well as healthcare services companies. Baird Venture Partners is based in Chicago, and invests in national opportunities.

BioFusion Capital (Australia)

BioFusion Capital was formed in March 2002 and was granted registration as a Pooled Development Fund in May 2002. You may not think of Australia when comes to healthcare / medical investments, in fact, Australia has enjoyed some successes with a number of global players; notably CSL, Cochlear, ResMed and iSoft (IBA Health). Australian venture capital firms have enjoyed some exceptional successes especially in the areas of medical devices.

Abingworth (UK)

London based Abingworth is a long-established venture capital firm dedicated to the life sciences sector on both sides of the Atlantic. The company invests across all stages of development, including early-stage as well as public companies. Its focus are in building up early and late stage medical companies, typically investing in the range of $20 to $80 million, Abinworth is an international investor, although its primary focus are US, UK and Europe. The company will also invest in public listed early stage healthcare companies.

We hope you find these profile of healthcare / medical investors of use and interest. For more information about Global investors in the healthcare, medical and pharmaceutical sectors, please check out our Global Biotechnology Capital Providers Guide on http://researchwhitepaper.com